Bethune GC - Search Results

1

Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?

Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ. Bethune GC, et al. Histopathology. 2017 May;70(6):966-974. doi: 10.1111/his.13160. Epub 2017 Feb 24. Histopathology. 2017. PMID: 28032917

2

HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?

Bethune GC, Mullen JB, Chang MC. Bethune GC, et al. Am J Clin Pathol. 2013 Oct;140(4):588-92. doi: 10.1309/AJCPZSV2W1CPGRJW. Am J Clin Pathol. 2013. PMID: 24045558

3

Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.

Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ. Bethune GC, et al. Histopathology. 2015 Dec;67(6):880-7. doi: 10.1111/his.12723. Epub 2015 Jun 9. Histopathology. 2015. PMID: 25913507

4

Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks.

Bethune GC, Mullen JB, Chang MC. Bethune GC, et al. Ann Diagn Pathol. 2015 Dec;19(6):385-90. doi: 10.1016/j.anndiagpath.2015.08.001. Epub 2015 Aug 15. Ann Diagn Pathol. 2015. PMID: 26372078

5

Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive Breast Carcinoma: A Cohort Analysis.

Bethune GC, Karkada MA, DeCoste R, Barnes PJ, Rayson D. Bethune GC, et al. Clin Breast Cancer. 2019 Aug;19(4):286-291. doi: 10.1016/j.clbc.2019.03.002. Epub 2019 Mar 11. Clin Breast Cancer. 2019. PMID: 31078418

6

Cystic neutrophilic granulomatous mastitis - a review of 12 consecutive cases.

Maung MH, Bethune GC, Patriquin G, Barnes PJ. Maung MH, et al. Among authors: bethune gc. Histopathology. 2020 Nov;77(5):781-787. doi: 10.1111/his.14187. Epub 2020 Sep 12. Histopathology. 2020. PMID: 32557756

7

Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.

Taylor VJ, Barnes PJ, Godwin SC, Bethune GC. Taylor VJ, et al. Among authors: bethune gc. Virchows Arch. 2021 Jul;479(1):23-31. doi: 10.1007/s00428-021-03034-4. Epub 2021 Feb 1. Virchows Arch. 2021. PMID: 33527151

8

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

Liwski CR, Castonguay MC, Barnes PJ, Rayson D, Bethune GC. Liwski CR, et al. Among authors: bethune gc. Ann Diagn Pathol. 2022 Aug;59:151953. doi: 10.1016/j.anndiagpath.2022.151953. Epub 2022 Apr 21. Ann Diagn Pathol. 2022. PMID: 35487077

9

Using Deep Learning to Predict Final HER2 Status in Invasive Breast Cancers That are Equivocal (2+) by Immunohistochemistry.

Rasmussen SA, Taylor VJ, Surette AP, Barnes PJ, Bethune GC. Rasmussen SA, et al. Among authors: bethune gc. Appl Immunohistochem Mol Morphol. 2022 Nov-Dec 01;30(10):668-673. doi: 10.1097/PAI.0000000000001079. Epub 2022 Oct 17. Appl Immunohistochem Mol Morphol. 2022. PMID: 36251973

10

ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.

Bharadwaj AG, McLean ME, Dahn ML, Cahill HF, Wasson MD, Arun RP, Walker OL, Cruickshank BM, Fernando W, Venkatesh J, Barnes PJ, Bethune G, Knapp G, Helyer LK, Giacomantonio CA, Waisman DM, Marcato P. Bharadwaj AG, et al. Mol Oncol. 2024 Jan;18(1):91-112. doi: 10.1002/1878-0261.13528. Epub 2023 Oct 9. Mol Oncol. 2024. PMID: 37753740 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page